Download
13046_2024_Article_3153.pdf 1,85MB
WeightNameValue
1000 Titel
  • Circulating tumour DNA dynamics predict recurrence in stage III melanoma patients receiving neoadjuvant immunotherapy
1000 Autor/in
  1. Chan, Wei Yen |
  2. Lee, Jenny H. |
  3. Stewart, Ashleigh |
  4. Diefenbach, Russell J. |
  5. Gonzalez, Maria |
  6. Menzies, Alexander M. |
  7. Blank, Christian |
  8. Scolyer, Richard A. |
  9. Long, Georgina V. |
  10. Rizos, Helen |
1000 Verlag BioMed Central
1000 Erscheinungsjahr 2024
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2024-08-21
1000 Erschienen in
1000 Quellenangabe
  • 43(1):238
1000 Copyrightjahr
  • 2024
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1186/s13046-024-03153-1 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11337884/ |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • <jats:title>Abstract</jats:title><jats:sec> <jats:title>Background</jats:title> <jats:p>Neoadjuvant therapy improves recurrence-free survival (RFS) in resectable stage III cutaneous melanoma. However, accurately predicting individual recurrence risk remains a significant challenge. We investigated circulating tumour DNA (ctDNA) as a biomarker for recurrence in measurable stage IIIB/C melanoma patients undergoing neoadjuvant immunotherapy.</jats:p> </jats:sec><jats:sec> <jats:title>Methods</jats:title> <jats:p>Plasma samples were collected pre-neoadjuvant treatment, pre-surgery and/or six weeks post-surgery from 40 patients enrolled in the OpACIN-neo and PRADO clinical trials. Patients received two cycles of ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1) before surgery. Cell free DNA (cfDNA) underwent unbiased pre-amplification followed by tumour-informed mutation detection using droplet digital polymerase chain reaction (ddPCR) with the Bio-Rad QX600 PCR system.</jats:p> </jats:sec><jats:sec> <jats:title>Results</jats:title> <jats:p>Pre-treatment ctDNA was detectable in 19/40 (48%) patients. Among these, 17/19 (89%) zero-converted within six weeks of surgery and none recurred. Positive ctDNA post-surgery (<jats:italic>N</jats:italic> = 4), irrespective of pre-treatment ctDNA status, was 100% predictive of recurrence (sensitivity 44%, specificity 100%). Furthermore, ctDNA cleared prior to surgery in 7/9 (78%) patients who did not recur, warranting further investigation into ctDNA-guided surgical management.</jats:p> </jats:sec><jats:sec> <jats:title>Conclusion</jats:title> <jats:p>Post-surgery ctDNA positivity and zero-conversion are highly predictive of recurrence, offering a window for personalised modification of adjuvant therapy.</jats:p> </jats:sec>
1000 Sacherschließung
lokal Melanoma/therapy [MeSH]
lokal Circulating Tumor DNA/genetics [MeSH]
lokal Aged [MeSH]
lokal Skin Neoplasms/blood [MeSH]
lokal Neoadjuvant Therapy/methods [MeSH]
lokal Neoplasm Staging [MeSH]
lokal Immunotherapy/methods [MeSH]
lokal Male [MeSH]
lokal Neoadjuvant therapy
lokal Melanoma/pathology [MeSH]
lokal Circulating tumour DNA
lokal Neoplasm Recurrence, Local [MeSH]
lokal Liquid Biopsy in Precision Oncology
lokal Melanoma/drug therapy [MeSH]
lokal Female [MeSH]
lokal Circulating Tumor DNA/blood [MeSH]
lokal Melanoma/genetics [MeSH]
lokal Adult [MeSH]
lokal Humans [MeSH]
lokal Melanoma/blood [MeSH]
lokal Middle Aged [MeSH]
lokal Skin Neoplasms/pathology [MeSH]
lokal Skin Neoplasms/genetics [MeSH]
lokal Biomarkers, Tumor/blood [MeSH]
lokal Research
lokal Stage III melanoma
lokal Skin Neoplasms/therapy [MeSH]
lokal Recurrence risk
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/Q2hhbiwgV2VpIFllbg==|https://frl.publisso.de/adhoc/uri/TGVlLCBKZW5ueSBILg==|https://frl.publisso.de/adhoc/uri/U3Rld2FydCwgQXNobGVpZ2g=|https://frl.publisso.de/adhoc/uri/RGllZmVuYmFjaCwgUnVzc2VsbCBKLg==|https://frl.publisso.de/adhoc/uri/R29uemFsZXosIE1hcmlh|https://frl.publisso.de/adhoc/uri/TWVuemllcywgQWxleGFuZGVyIE0u|https://frl.publisso.de/adhoc/uri/QmxhbmssIENocmlzdGlhbg==|https://frl.publisso.de/adhoc/uri/U2NvbHllciwgUmljaGFyZCBBLg==|https://frl.publisso.de/adhoc/uri/TG9uZywgR2VvcmdpbmEgVi4=|https://orcid.org/0000-0002-2094-9198
1000 Hinweis
  • DeepGreen-ID: d349a5e3a2bd4158b1150be86c8d63f3 ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Förderer
  1. National Health and Medical Research Council |
  2. CLEARbridge Foundation |
  3. Tour de Cure |
1000 Fördernummer
  1. -
  2. -
  3. -
1000 Förderprogramm
  1. -
  2. -
  3. -
1000 Dateien
1000 Förderung
  1. 1000 joinedFunding-child
    1000 Förderer National Health and Medical Research Council |
    1000 Förderprogramm -
    1000 Fördernummer -
  2. 1000 joinedFunding-child
    1000 Förderer CLEARbridge Foundation |
    1000 Förderprogramm -
    1000 Fördernummer -
  3. 1000 joinedFunding-child
    1000 Förderer Tour de Cure |
    1000 Förderprogramm -
    1000 Fördernummer -
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6513184.rdf
1000 Erstellt am 2025-07-03T23:27:54.328+0200
1000 Erstellt von 322
1000 beschreibt frl:6513184
1000 Zuletzt bearbeitet 2025-08-15T19:54:43.106+0200
1000 Objekt bearb. Fri Aug 15 19:54:43 CEST 2025
1000 Vgl. frl:6513184
1000 Oai Id
  1. oai:frl.publisso.de:frl:6513184 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source